Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics

Pharmacological Research

Volumn 106, Issue , 2016, Pages 72-86

  Spina, Edoardo ^a   Pisani, Francesco ^a   De Leon, Jose ^b,c,d  

^a UNIVERSITY OF MESSINA   (Italy)

^b Eastern State Hospital   (United States)

^c UNIVERSITY OF GRANADA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antidepressants; Antiepileptics; Antipsychotics; Drug interactions; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOBAZAM; CLOZAPINE; ESLICARBAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RETIGABINE; RUFINAMIDE; STIRIPENTOL; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CONFUSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; EPILEPSY; FATIGUE; HUMAN; MONOTHERAPY; MYOCARDITIS; PRIORITY JOURNAL; PROTEIN BINDING; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SEDATION; SIDE EFFECT; STEVENS JOHNSON SYNDROME; UNSPECIFIED SIDE EFFECT; DRUG INTERACTION;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; HUMANS;

EID: 84959165252     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.02.014     Document Type: Review

References (129)

1. E. Spina, and D. Italiano Drug interactions S. Shorvon, E. Perucca, J. Engel, Treatment of Epilepsy 4th ed. 2015 Wiley-Blackwell Publishing Ltd. Oxford 344 359
2. E. Perucca Clinically relevant drug interactions with antiepileptic drugs Br. J. Clin. Pharmacol. 61 2006 246 255
3. E. Spina, and E. Perucca Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs Epilepsia 43 Suppl. 2 2002 37 44
4. S.M. Stahl Antidepressants S.M. Stahl, Stahl's Essential Psychopharmacology 4th ed. 2013 Cambridge University Press New York 284 369
5. S.M. Stahl Antipsychotic agents S.M. Stahl, Stahl's Essential Psychopharmacology 4th ed. 2013 Cambridge University Press New York 129 236
6. P.N. Patsalos, and E. Perucca Clinically important drug interactions in epilepsy: General features and interactions between antiepileptic drugs Lancet Neurol. 2 2003 347 356
7. P.N. Patsalos, and E. Perucca Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs Lancet Neurol. 2 2003 473 481
8. C. Johannesen Landmark, and P. Patsalos Drug interactions involving the new second- and third-generation antiepileptic drugs Expert Rev. Neurother. 10 2010 119 140
9. G. Zaccara, and E. Perucca Interactions between antiepileptic drugs: And between antiepileptic drugs and other drugs Epileptic. Disord. 16 2014 409 431
10. P.N. Patsalos Drug interactions with newer antiepileptic drugs (AEDs)-part 1: Pharmacokinetic and pharmacodynamic interactions between AEDs Clin. Pharmacokinet. 52 2013 927 966
11. P.N. Patsalos Drug interactions with newer antiepileptic drugs (AEDs)-part 2: Pharmacokinetic and pharmacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders Clin. Pharmacokinet. 52 2013 1045 1061
12. E. Spina, V. Santoro, and C. D'Arrigo Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update Clin. Ther. 30 2008 1206 1227
13. E. Spina, G. Trifirò, and F. Caraci Clinically significant drug interactions with newer antidepressants CNS Drugs 26 2012 39 67
14. E. Spina, and J. de Leon Metabolic drug interactions with newer antipsychotics: A comparative review Basic Clin. Pharmacol. Toxicol. 100 2007 4 22
15. W.K. Kennedy, M.W. Jann, and E.C. Kutscher Clinically significant drug interactions with atypical antipsychotics CNS Drugs 12 2013 1021 1048
16. M. Mula, and F. Monaco Antiepileptic-antipsychotic drug interactions: A critical review of the evidence Clin. Neuropharmacol. 25 2002 280 289
17. F.M.C. Besag, and D. Berry Interactions between antiepileptic and antipsychotic drugs Drug Saf. 29 2006 95 118
18. M. Mula Anticonvulsants-antidepressants pharmacokinetic drug interactions: The role of the CYP450 system in psychopharmacology Curr. Drug Metab. 8 2008 730 737
19. J. de Leon, V. Santoro, C. D'Arrigo, and E. Spina Interactions between antiepileptics and second-generation antipsychotics Exp. Opin. Drug Metab. Toxicol. 8 2012 311 334
20. D. Italiano, E. Spina, and J. de Leon Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants Exp. Opin. Drug Metab. Toxicol. 10 2014 1457 1489
21. K.L. Cozza, S.C. Armstrong, and J.R. Oesterheld Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-Glycoproteins 2nd ed. 2003 American Psychiatric Association Washington, DC
22. J.H. Lin Transporter-mediated drug interactions. Clinical implications and in vitro assessment Exp. Opin. Drug Metab. Toxicol. 3 2007 81 92
23. C. Zhang, P. Kwan, Z. Zuo, and L. Baum The transport of antiepileptic drugs by P-glycoprotein Adv. Drug Deliv. Rev. 64 2012 930 942
24. F.E. O'Brien, T.G. Dinan, B.T. Griffin, and J.F. Cryan Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: Clinical significance of in vitro and in vivo findings Br. J. Pharmacol. 165 2012 289 312
25. T. Moons, M. de Roo, S. Clees, and G. Dom Relationship between P-glycoprotein and second generation antipsychotics Pharmacogenomics 12 2011 1193 1211
26. Y. Akamine, N. Yasui-Furukori, I. Ieiri, and T. Uno Psychotropic drug-drug interactions involving P-glycoprotein CNS Drugs 26 2012 959 973
27. A.M. Kanner The treatment of depressive disorders in epilepsy: What all neurologists should know Epilepsia 54 2013 3 12
28. P. Mehndiratta, and M. Sajatovic Treatments for patients with comorbid epilepsy and depression: A systematic literature review Epilepsy Behav. 28 2013 36 40
29. L.N. Yatham, S.H. Kennedy, S.V. Parikh, and et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013 Bipolar Disord. 15 2013 1 44
30. K. Rickels, T.M. Shiovitz, T.S. Ramey, and et al. Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment Int. Clin. Psychopharmacol. 27 2012 142 150
31. L.E. Chaparro, P.J. Wiffen, R.A. Moore, and I. Gilron Combination pharmacotherapy for the treatment of neuropathic pain in adults Cochrane Database Syst. Rev. 7 2012 CD008943
32. I. Gilron, T.S. Jensen, and A.H. Dickenson Combination pharmacotherapy for management of chronic pain: from bench to bedside Lancet Neurol. 12 2013 1084 1095
33. W.H. Greb, G. Buscher, H.D.H.D. Dierdorf, and et al. The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine Acta Psychiatry Scand. 350 Suppl 1989 95 98
34. B.B. Andersen, M. Mikkelsen, A. Vesterager, and et al. No influence of the antidepressant paroxetine on carbamazepine valproate and phenytoin Epilepsy Res. 10 1991 201 204
35. A. Kahn, M.U. Shad, and S.H. Preskhorn Lack of sertraline efficacy probably due to an interaction with carbamazepine J. Clin. Psychiatry 61 2000 526 527
36. M. Pihlsgard, and E. Eliasson Significant reduction of sertraline plasma levels by carbamazepine and phenytoin Eur. J. Clin. Pharmacol. 57 2002 915 916
37. L. Steinacher, P. Vandel, D.F. Zullino, and et al. Carbamazepine augmentation in depressive patients non-responding to citalopram: A pharmacokinetic and clinical pilot study Eur. Neuropsychopharmacol. 12 2002 255 260
38. C. Puozzo, and B.E. Leonard Pharmacokinetics of milnacipran in comparison with other antidepressants Int. Clin. Psychopharmacol. 11 Suppl. 4 1996 15 27
39. J. Sitsen, F. Maris, and C. Timmer Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects Eur. J. Drug Metab. Pharmacokinet. 26 2001 109 121
40. E. Spaans, M.W. van den Heuvel, P.G. Schnabel, and et al. Concomitant use of mirtazapine and phenytoin: A drug-drug interactions study in healthy male subjects Eur. J. Clin. Pharmacol. 58 2002 423 429
41. T.A. Ketter, J.B. Jenkins, D.H. Schroeder, and et al. Carbamazepine but not valproate induces bupropion metabolism J. Clin. Psychopharmacol. 15 1995 327 333
42. A. Helland, and O. Spigset Low serum concentrations of reboxetine in 2 patients treated with CYP3A4 inducers J. Clin. Psychopharmacol. 27 2007 308 310
43. J. de Leon False-negative studies may systematically contaminate the literature on the effects of inducers in neuropsychopharmacology. Part II: focus on bipolar disorder J. Clin. Psychopharmacol. 34 2014 291 296
44. S. Unterecker, A. Reif, S. Hempel, and et al. Interaction of valproic acid and the antidepressants doxepin and venlafaxine: Analysis of therapeutic drug monitoring data under naturalistic conditions Int. Clin. Psychopharmacol. 29 2014 206 211
45. P. Jalil Toxic reaction following the combined administration of fluoxetine and phenytoin: Two case reports J. Neurol. Neurosurg. Psychiatry 55 1992 412 413
46. J. Darley Interaction between phenytoin and fluoxetine Seizure 3 1994 151 152
47. D.J. Woods, D.M. Coulter, and P. Pillans Interaction of phenytoin and fluoxetine NZ Med. J. 107 1994 19
48. R. Sovner, and J.M. Davis A potential drug interaction between fluoxetine and valproic acid J. Clin. Psychopharmacol. 11 1991 389
49. S. Cruz-Flores, G.R. Hayat, and W. Mirza Valproic acid toxicity with fluoxetine therapy MO Med. 92 1995 296 297
50. M.I. Lucena, E. Blanco, M.A. Corrales, and M.L. Berthier Interaction of fluoxetine and valproic acid Am. J. Psychiatry 155 1998 575
51. H.J. Pearson Interaction of fluoxetine with carbamazepine J. Clin. Psychiatry 51 1990 126
52. S.R. Grimsley, M.W. Jann, J.G. Carter, and et al. Increased carbamazepine plasma concentrations after fluoxetine coadmnistration Clin. Pharmacol. Ther. 50 1991 10 15
53. E. Spina, A. Avenoso, A.M. Pollicino, and et al. Carbamazepine coadministration with fluoxetine or fluvoxamine Ther. Drug Monit. 15 1993 247 250
54. A. Reimers, E. Skogvoll, J.K. Sund, and O. Spigset Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service J. Clin. Psychopharmacol. 25 2005 342 348
55. J. Fritze, B. Unsorg, and M. Lanczik Interaction between carbamazepine and fluvoxamine Acta Psychiatry Scand. 84 1991 583 584
56. P. Bonnet, S. Vandel, S. Nezelof, and et al. Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction? Therapie 47 1992 165
57. K. Mamiya, K. Kojima, E. Yukawa, and et al. Phenytoin intoxication induced by fluvoxamine Ther. Drug Monit. 23 2001 75 77
58. W.G. Rapeport, S.A. Williams, D.C. Muirhead, and et al. Absence of sertraline-mediated effect of the pharmacokinetics and pharmacodynamics of carbamazepine J. Clin. Psychiatry 57 Suppl. 1 1996 20 23
59. W.G. Rapeport, D.C. Muirhead, S.A. Williams, and et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin J. Clin. Psychiatry 57 Suppl. 1 1996 24 28
60. T.R. Berigan, and J. Harazin A sertraline/valproic acid drug interaction Int. J. Psychiatr. Clin. Pract. 3 1999 287 288
61. K.R. Kaufman, and R. Gerner Lamotrigine toxicity secondary to sertraline Seizure 7 1998 163 165
62. J. Christensen, A.P. Sandgaard, P. Sidenius, and et al. Lack of interaction between sertraline and lamotrigine in psychiatric patients: A retrospective study Pharmacopsychiatry 45 2012 119 121
63. S.E. Moller, F. Larsen, A.Z. Khan, and P.E. Rolan Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects J. Clin. Psychopharmacol. 21 2001 493 499
64. A. Sanchez-Romero, A. Mayordomo-Aranda, R. Garcia-Delgado, and J.A. Duran-Quintana Probable interaction between trazodone and carbamazepine Pharmacopsychiatry 44 2011 158 159
65. A.P. Popli, J. Tanquary, V. Lamparella, and P.S. Masand Bupropion and anticonvulsant drug interactions Ann. Clin. Psychiatry 7 1995 99 101
66. J. Odishaw, and C. Chen Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects Pharmacotherapy 20 2000 1448 1453
67. M. Jerling, L. Lindstrom, U. Bondesson, and L. Bertilsson Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service Ther. Drug Monit. 16 1994 368 374
68. J. Tiihonen, H. Bartiainen, and P. Hakola Carbamazepine-induced changes in plasma levels of neuroleptics Pharmacopsychiatry 28 1995 26 28
69. R.A. Lucas, D.J. Gilfillan, and R.F. Bergstrom A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanisms Eur. J. Clin. Pharmacol. 54 1998 639 643
70. O.V. Olesen, and K. Linnet Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication Ther. Drug Monit. 21 1999 87 90
71. K. Linnet, and O.V. Olesen Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication Ther. Drug Monit. 24 2002 512 517
72. E. Skogh, M. Reis, M. Dahl, and et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting Ther. Drug Monit. 24 2002 518 526
73. S. Botts, F.J. Diaz, V. Santoro, and et al. Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model Progr. Neuro Psychopharmacol. Biol. Psychiatry 32 2008 1453 1458
74. T. Haslemo, K. Olsen, H. Lunde, and E. Molden Valproic acid significantly lowers serum concentrations of olanzapine. An interaction effect comparable with smoking Ther. Drug Monit. 34 2012 512 517
75. S.W. Grimm, N.M. Richtand, H.R. Winter, and et al. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics Br. J. Clin. Pharmacol. 61 2006 58 66
76. J. Hasselstrom, and K. Linnet Quetiapine serum concentrations in psychiatric patients Ther. Drug Monit. 26 2004 486 491
77. I. Castberg, E. Skogvoll, and O. Spigset Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service J. Clin. Psychiatry 68 2007 1540 1545
78. V. Santoro, C. D'Arrigo, G. Migliardi, and et al. Therapeutic drug monitoring of quetiapine: effect of coadministration with antiepileptic drugs in patients with psychiatric disorders Open Clin. Chem. J. 1 2008 17 21
79. M. Wittman, H. Hauser, A. Köstlbacher, and et al. Individual clearance and therapeutic drug monitoring of quetiapine in clinical practice Neuroendocrinol. Lett. 31 2010 203 207
80. T. Nicki-Jockschat, M. Paulzen, F. Schneider, and et al. Drug interaction can lead to undetectable serum concentrations of quetiapine in the presence of carbamazepine Clin. Neuropharmacol. 32 2009 5
81. J. de Leon, and J. Bork Risperidone and cytochrome P450 3A J. Clin. Psychiatry 58 1997 450
82. E. Spina, M.G. Scordo, A. Avenoso, and et al. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 J. Clin. Psychopharmacol. 21 2001 108 109
83. E. Spina, A. Avenoso, G. Facciolà, and et al. Plasma concentrations of risperidone and 9-hydroxy-risperidone effect of comedication with carbamazepine or valproate Ther Drug Monit. 22 2000 481 485
84. S. Ono, K. Mihara, A. Suzuki, and et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes Psychopharmacology 162 2002 50 54
85. N. Yasui-Furukori, K. Kubo, M. Ishioka, and et al. Interaction between paliperidone and carbamazepine Ther. Drug Monit. 35 2013 649 652
86. V. Kerbusch-Herben, A. Cleton, J. Berwaets, and et al. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady state Clin. Pharmacol. Drug Dev. 3 2014 1 7
87. J.J. Miceli, R.J. Anziano, L. Robarge, and et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers Br. J. Clin. Pharmacol. 49 2000 65S 70S
88. L. Citrome, J.P. Macher, D.E. Salazar, and et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine J. Clin. Psychopharmacol. 27 2007 279 283
89. A. Nakamura, K. Mihara, G. Nagai, and et al. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia Ther. Drug Monit. 31 2009 575 578
90. I. Castberg, and O. Spigset Effect of comedication on the serum level of aripiprazole: evidence from a routine therapeutic drug monitoring service Pharmacopsychiatry 40 2007 107 110
91. D.D. Miller Effect of phenytoin on plasma clozapine concentrations in two patients J. Clin. Psychiatry 52 1991 23 25
92. H.Y. Lane, K.P. Su, W.H. Chang, and et al. Elevated plasma clozapine concentrations after phenobarbital discontinuation J. Clin. Psychiatry 59 1998 131 133
93. G. Facciolà, A. Avenoso, E. Spina, and E. Perucca Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia Ther. Drug Monit. 20 1998 628 630
94. Y.W. Wong, C. Yeh, and P.T. Thyrum The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine J. Clin. Psychopharmacol. 21 2001 89 93
95. F. Centorrino, R.J. Baldessarini, J. Kando, and et al. Serum concentrations of clozapine and its metabolites: effects of cotreatment with fluoxetine or valproate Am. J. Psychiatry 151 1994 123 125
96. G. Facciolà, A. Avenoso, M.G. Scordo, and et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders Ther. Drug Monit. 21 1999 341 345
97. J.O. Wong, S.P. Leung, T. Mak, and et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients Prog. Neuro Psychopharmacol. Biol. Psychiatry 30 2006 251 264
98. A.P. Rajkumar, B. Poonkuzhali, A. Kuruvilla, and et al. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia Int. Clin. Psychopharmacol. 28 2013 50 56
99. P. Finley, and D. Warner Potential impact of valproic acid therapy on clozapine disposition Biol. Psychiatry 36 1994 487 488
100. F.J. Diaz, V. Santoro, E. Spina, and et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables Pharmacopsychiatry 41 2008 81 91
101. F.J. Diaz, C.B. Eap, N. Ansermot, and et al. Can valproic acid be an inducer of clozapine metabolism Pharmacopsychiatry 47 2014 89 96
102. A. Riesselman, B. Strobl, A.T. Cooley, and J. de Leon A case report that suggested that aspirin's effects on valproic acid metabolism may contribute to valproic acid's inducer effects on clozapine metabolism J. Clin. Psychopharmacol. 33 2013 812 814
103. N. Chopra, and J. de Leon Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy Int. J. Psychiatry Med. 51 2016 104 115
104. M. Gex-Fabry, A.E. Balant-Gorgia, and L. Balant Therapeutic drug monitoring of olanzapine: The combined effect of age gender, smoking, and comedication Ther. Drug Monit. 25 2003 46 53
105. N. Bergemann, K.R. Kress, F. Abu-Tair, and et al. Valproate lowers plasma concentration of olanzapine J. Clin. Psychopharmacol. 26 2006 432 434
106. E. Spina, C. D'Arrigo, V. Santoro, and et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder Ther. Drug Monit. 31 2009 758 763
107. W. Aichhorn, J. Marksteiner, T. Walch, and et al. Influence of age gender, body weight and valproate co-medication on quetiapine plasma concentrations Int. Clin. Psychopharmacol. 21 2006 81 85
108. H.R. Winter, C.L. DeVane, C. Figueroa, and et al. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia schizoaffective disorder, or bipolar disorder Hum. Psychopharmacol. Clin. Exp. 22 2007 469 476
109. A. Ravindran, P. Silverstone, D. Lacroix, and et al. Risperidone does not affect steady-state pharmacokinetics of divalproex sodium inpatients with bipolar disorder Clin. Pharmacokinet. 43 2004 733 740
110. L. Citrome, R. Josiassen, N. Bark, and et al. Pharmacokinetics of aripiprazole and concomitant lithium and valproate J. Clin. Pharmacol. 45 2005 89 93
111. M.G. Gerrits, R. de Greef, P. Dogterom, and et al. Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations J. Clin. Pharmacol. 52 2012 757 765
112. M. Kossen, J.P. Selten, and R.S. Kahn Elevated clozapine plasma level with lamotrigine Am. J. Psychiatry 158 2001 1930
113. J. Tiihonen, T. Hallikainen, O.P. Ryynanen, and et al. Lamotrigine in treatment-resistant schizophrenia: A randomized placebo-controlled crossover trial Biol. Psychiatry 54 2003 1241 1248
114. E. Spina, C. D'Arrigo, G. Migliardi, and et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine: risperidone and olanzapine in patients with schizophrenia or bipolar disorder Ther. Drug Monit. 28 2006 599 602
115. M.W. Jann, Y.Y. Hon, S.A. Shamsi, and et al. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers Pharmacotherapy 26 2006 627 633
116. J. Sidhu, S. Job, J. Bullman, and et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects Br. J Clin. Pharmacol. 61 2006 420 426
117. M.L. Andersson, L. Bjorkhem-Bergman, and J.D. Lindh Possible drug-druginteraction between quetiapine and lamotrigine-evidence from a Swedish TDM database Br. J. Clin. Pharmacol. 72 2011 153 156
118. S.D. Bienentreu, and K.T.H. Kronmuller Increase in risperidone plasma level with lamotrigine Am. J. Psychiatry 162 2005 811 812
119. R.B. Waade, H. Christensen, I. Rudberg, and et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole Ther. Drug Monit. 31 2009 233 238
120. M.R. Muscatello, M. Pacetti, M. Cacciola, and et al. Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine Epilepsia 46 2005 771 774
121. I.R. McGrane, J.G. Loveland, H.J. Zaluski, and K.D. Foster Serum quetiapine concentration changes with concomitant oxcarbazepine therapy in a boy with autism spectrum disorder J. Child Adolesc. Psychopharmacol. 25 2015 729 730
122. M. Bialer, D.R. Doose, B. Murthy, and et al. Pharmacokinetic interactions of topiramate Clin. Pharmacokinet. 43 2004 763 780
123. G. Migliardi, C. D'Arrigo, V. Santoro, and et al. Effect of topiramate on plasma concentrations of clozapine olanzapine, risperidone, and quetiapine in patients with psychotic disorders Clin. Neuropharmacol. 30 2007 107 113
124. M. Mula, and F. Monaco Carbamazepine-risperidone interaction in patients with epilepsy Clin. Neuropharmacol. 25 2002 97 100
125. B. Fitzgerald, and A. Okos Elevation of carbamazepine-10:11-epoxide by quetiapine Pharmacother. 22 2002 1500 1503
126. D.W. Boulton, G.D. Kollia, S. Mallikaarjun, and D.M. Kornhauser Lack of a pharmacokinetic drug-drug interaction between lithium andvalproate when co-administered with aripiprazole J. Clin. Pharm. Ther. 37 2012 565 570
127. A. Reimers, E. Skogvoll, J.K. Sund, and et al. Drug interaction between lamotrigine and psychoactive drugs J. Clin. Psychopharmacol. 25 2005 342 348
128. F.C. Schieber, D.W. Boulton, A.H. Balch, and et al. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder Hum. Psychopharmacol. Clin. Exp. 24 2009 145 152
129. J. de Leon, E. Spina, and F.J. Diaz Pharmacokinetic drug interaction studies must consider pharmacological heterogeneity use of repeated dosing, and translation into a message understandable to practicing clinicians J. Clin. Psychopharmacol. 29 2009 201 205